Does neuroprotection with NXY-059 improve patient outcome after acute ischemic stroke?
Marc Fisher
Correspondence Department of Neurology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
Email fisherm@ummhc.org
This article has no abstract so we have provided the first paragraph of the full text.
The only approved therapy for AIS is TPA administered within 3 h of stroke onset; this therapy, however, is employed in less than 5% of AIS patients in most hospitals.1 Thus, the need for additional AIS therapies is obvious. Thrombolysis to restore or enhance blood flow is not the only therapeutic approach for AIS; drugs designed to ameliorate or impede the cellular consequences of injury—neuroprotective drugs—can also be used.2
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
